Arguing Class Actions is a monthly column for the National Law Journal written by DiCello Levitt's Adam J. Levitt.

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Circuits that bar fail-safe classes, Hilton said, have found an implied “definiteness” requirement in Rule 23 that mandates a precise, objective definition of who is in the class.

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation ...